<unk> , sold under the brand name Juluca, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains the medicines dolutegravir and rilpivirine. It is taken by mouth. The most common adverse reactions (of all severity grades) are diarrhea and headache.<unk>  was approved for use in the United States in November 2017, and for use in the European Union in May 2018.
Dolutegravir/rilpivirine
Atazanavir/cobicistat
Atazanavir/ritonavir
Cabotegravir/rilpivirine
Darunavir/cobicistat
Dolutegravir/lamivudine
Lamivudine/raltegravir
Nirmatrelvir/ritonavir